Description
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1 and 2 bp insertion in exon1.
Product details:
Western blot data indicates that the CRISPR gene edit may have resulted in a truncation of the protein of interest. Please see data images.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-BCR, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The Bcr protein also known as breakpoint cluster region protein plays an important role in cellular signaling. It has a molecular mass of approximately 160 kDa and is expressed in many cell types such as hematopoietic cells. Bcr functions as a GTPase-activating protein (GAP) for p21rac and other small GTP-binding proteins. This activity influences cellular processes such as growth and differentiation. Bcr is also known for its involvement in the formation of the Bcr-Abl fusion protein an important factor in certain leukemias.
Biological function summary
The Bcr protein acts within cells to regulate signal transduction and cytoskeletal organization. It is part of the pre-B cell receptor (pre-BCR) signaling complex influencing B-cell development. Its GAP activity is important for the regulation of small GTPases impacting cell migration and adhesion. Alterations in Bcr function can affect cellular responses such as apoptosis making it a focus for research into targeted therapies for hematological conditions.
Pathways
The Bcr protein is an important player in signaling pathways involving the Ras superfamily of small GTPases. It is notably involved in the Rho GTPase pathway tied to cytoskeletal dynamics and cell cycle progression. Bcr's interaction with these pathways puts it in relation to proteins like Rac and Cdc42 which are vital for various cellular processes. Disruption in Bcr-associated pathways can lead to aberrant cell growth and metastasis.
Bcr has a well-documented link to certain leukemias particularly chronic myeloid leukemia (CML). The Bcr-Abl fusion protein resulting from the translocation of chromosomes 9 and 22 is central to CML pathology. Additionally Bcr connects with other proteins such as Abl in this disease context. Further disruptions in Bcr signaling can relate to disorders involving immune system dysregulation demonstrating the protein's relevance in both oncology and immunology research.
